Comparison and quantitation of alleles in lymphoid subsets. (A) The percentage contribution of each PBMC subset to the total mutation burden (obtained by summing the parts) among CD3⁺ T cells, CD19⁺ B cells, and myeloid cells (monocytes and DCs). (B) The percentage contribution of each T-cell subset to the mutation burden present in T cells among naïve, central memory (CM), effector memory (EM), and effector memory cells re-expressing CD45RA (TEMRA). Supplemental Figure 1 shows the sorting strategy. In panels A and B, the graphs show data from 1 late time point of all patients with a sufficient material available (n = 13; analysis of variance). (C) Summary of the mutant allele fraction in PBMC in all samples as a function of time on treatment. (D) Summary of the percentage contribution from T cells (green) and all myeloid cells (red) to the total mutation burden of these subsets as a function of time since diagnosis (n = 33). Broken lines depict the 95% confidence intervals for a simple linear regression. Dabra, dabrafenib; NK, natural killer; Tram, trametinib; Vem, vemurafenib.